Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients

Figures & data

Table 1. Clinical characteristics of fusion genes in non-adenocarcinoma NSCLC patients.

Case	Gender/age	Stage at diagnosis	Smoking status	Pack years	Histology	Gene type	Crizotinib treatment	Crizotinib PFS	OS
1	F/64	IIB	Non-smoking	0	Adenosquamous	ROS1	No	—	42M+
2	M/55	IB	Non-smoking	0	Adenosquamous	ALK	No	—	66.2M
3	M/42	IIIA	Non-smoking	0	Adenosquamous	ALK	No	—	34.5M
4	M/44	IIA	Current	10	Adenosquamous	ALK	No	—	50.4M
5	M/54	IIIA	Non-smoking	0	Adenosquamous	RET	No	—	32.4M
6	M/55	IA	Current	20	Adenosquamous	ALK	Yes	9.5M	66.5M
7	F/45	IIIA	Non-smoking	0	Adenosquamous	RET	Yes	7.0M	36.7M
8	M/56	IIIA	Non-smoking	0	SCC	ALK	Yes	8.0M	27.5M
9	M/39	IIB	Current	5	SCC	ALK	No	—	28.0M+
10	M/39	IIB	Non-smoking	0	SCC	ROS1	No	—	26.0M+
11	F/55	IB	Non-smoking	0	SCC	ROS1	No	—	29.0M+
12	F/42	IIIA	Non-smoking	0	LCC	ALK	No	—	21.0M

Abbreviations: M, male; F, female; SCC, squamous cell carcinoma; LCC, large cell carcinoma; OS, overall survival; M, month.

Table 2. Comparison of clinical characteristics between fusion gene positive and negative subjects.

	Fusion positive (n = 12)	Fusion negative (n = 373)	P
Gender			0.68
Male	8	210
Female	4	163
Age			0.02
﹤60	11	202
≥60	1	171
Smoking status			0.01
Never	9	132
Former/current	3	241
Pathologic stage			0.69
I+II	7	196
IIIA	5	177

Figure 1. (a) Thoracic computed tomography before crizotinib treatment (b) 2 months after crizotinib treatment.

Figure 2. Comparison of overall survival between fusion positive and negative patients.